Real-World Data on Faricimab Switching in Treatment-Refractory Neovascular Age-Related Macular Degeneration [PDF]
LifeFaricimab is a newly approved bispecific antibody for neovascular age-related macular degeneration (nAMD). Our study aims to evaluate clinical outcomes of faricimab switching in patients with treatment-refractory nAMD; determine parameters that predict ...
Yu Jeat Chong +2 more
exaly +5 more sources
Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials [PDF]
Ophthalmology and Therapy, 2023 Introduction This review aims to assess the efficacy, durability and safety of faricimab—a dual vascular endothelial growth factor and angiopoietin 2 inhibitor—in patients with neovascular age-related macular degeneration (nAMD) and diabetic macula ...
Jakob Grauslund, Anna Stage Vergmann
exaly +3 more sources
Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept
Medicina (Lithuania), 2023 Background and Objectives: Faricimab is the first intravitreal injection of vascular endothelial growth factor-A and angiopoietin-2 bispecific monoclonal antibody.
Yosuke Harada +2 more
exaly +4 more sources
Case Reports in Ophthalmology, 2023 This case report describes a 78-year-old patient who developed a tear of the retinal pigment epithelium (RPE) during faricimab (Vabysmo®) therapy. After three consecutive intravitreal aflibercept (Eylea®) injections with persistent disease activity ...
Christoph R Clemens +3 more
doaj +3 more sources
Early Macular Leakage Resolution Is Associated with Extended Faricimab Dosing in Retinal Vein Occlusion: A BALATON/COMINO Post Hoc Analysis [PDF]
Ophthalmology and TherapyIntroduction Macular leakage (ML) is a biomarker of disease activity and, in retinal vein occlusion (RVO), is associated with poor vision outcomes.
Christiana Dinah +9 more
doaj +2 more sources
Four-Year Outcomes of Faricimab in Diabetic Macular Edema in the RHONE-X Extension Trial: A Podcast [PDF]
Ophthalmology and TherapyDiabetic macula edema (DME) is a leading cause of vision loss among people with diabetes and requires long-term management strategies that balance efficacy, safety, and durability.
Veeral S. Sheth, Stela Vujosevic
doaj +2 more sources
Summary of Research: Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results From the RHONE-X Extension Trial [PDF]
Ophthalmology and TherapyThis is a summary of the original article “Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results From the RHONE-X Extension Trial.” RHONE-X was a phase 3, multicenter, nonrandomized, 2-year open-label extension of the YOSEMITE/RHINE clinical
Veeral S. Sheth +4 more
doaj +2 more sources
Early Real-World Experience of Switching to Faricimab for Macular Oedema Secondary to Vein Occlusion [PDF]
LifeAim: To evaluate the real-world effectiveness, durability, and safety of faricimab 6 mg in eyes with treatment-refractory retinal vein occlusion (RVO)-associated macular oedema (MO) in the United Kingdom (UK).
Muiz Musadiq +5 more
doaj +2 more sources
International Journal of Retina and Vitreous, 2023 Background Intravitreal injection (IVI) of antibody biologics is a key treatment approach in ophthalmology. Pharmaceutical compounding and storage of prefilled syringes for IVI must take place without impairing the structure and function of the biologics.
Øystein Kalsnes Jørstad +9 more
doaj +1 more source
Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration
Scientific Reports, 2023 Though vascular endothelial growth factors (VEGF) and other proangiogenic factors, such as angiopoietins (Ang), may be involved in the development of neovascular age-related macular degeneration (nvAMD), only drugs that inhibit the VEGF family are ...
Ryosuke Tamiya +12 more
doaj +1 more source